1124P - Treatment patterns and disease burden of stage IIIB/IIIC melanoma in France, Germany and the UK

Date 28 September 2014
Event ESMO 2014
Session Poster Display session
Topics Cancer Aetiology, Epidemiology, Prevention
Melanoma and other Skin Tumours
Presenter Peter Mohr
Citation Annals of Oncology (2014) 25 (suppl_4): iv374-iv393. 10.1093/annonc/mdu344
Authors P. Mohr1, M. Harries2, F. Grange3, R. Ehness4, L. Benjamin5, O. Siakpere6, L. McLeod7, S. Wolowacz8, J. Kaye9, I. Kontoudis10
  • 1Clinic Of Dermatology, Dermatologic Center Buxtehude, 21614 - Buxtehude/DE
  • 2Department Of Medical Oncology, Guys and St Thomas’s Hospitals NHS Foundation Trust, Guys Hospital, SE1 9RT - London/GB
  • 3Dermatology, Reims University Hospital, Reims/FR
  • 4Medical Hematology/oncology, GlaxoSmithKline GmbH & Co KG, Muenchen/DE
  • 5Health Economics And Outcomes Research, GlaxoSmithKline France, Marly le Roi/FR
  • 6Medical, GlaxoSmithKline UK, Middlesex/GB
  • 7Patient-reported Outcomes, RTI Health Solutions, Research Triangle Park/US
  • 8Health Economics, RTI Health Solutions, Manchester/GB
  • 9Epidemiology, RTI Health Solutions, Waltham/US
  • 10Itx, GlaxoSmithKline Vaccines, 1330 - Rixensart/BE

Abstract

Aim

Real-world data on treatment patterns and costs are often scarce, although much needed for health technology assessments governing patient access in many countries. This study aimed to collect these data in France, Germany and the UK for patients with stage IIIB/IIIC melanoma with macroscopic lymph node involvement, whose primary melanoma and regional lymph node metastases had been completely resected.

Methods

This retrospective observational study enrolled patients aged ≥18 years first diagnosed between 1 January 2009 and 31 December 2011. Data were extracted from patients' medical records until death or study end date, and via a patient survey. Costs were calculated by collecting resource use and multiplying by unit costs.

Results

49 centres provided data on 558 patients. Overall, 56% of patients were male and 58% were aged <65 years at diagnosis. Over half had stage IIIB disease. The mean total direct cost per patient over the entire medical record follow-up period was €23,582 in France, €32,058 in Germany, and £31,123 (€35,791) in the UK. The table shows the use of adjuvant systemic therapies in each country.

Adjuvant systemic therapy received, n (%)

France Germany UK
None 185 (93.0) 109 (66.5) 190 (97.4)
Interferon
High dose 3 (1.5) 18 (11.0)   0
intermediate dose 1 (0.5) 8 (4.9)   0
low dose 0 25 (15.2)   0
pegylated 0 3 (1.8)   0
Other 10 (5.0) 1 (0.6)   5 (2.6)
Total 199 164 195

Conclusions

Although the great majority of patients received no adjuvant treatment in France (93%) and the UK (97.4%), there was some use of interferon in Germany (high dose 11%; intermediate dose 5%; low dose 15%; pegylated 2%). Relatively high direct costs were observed in all three countries.

Disclosure

P. Mohr: PM received consulting fees and honoraria fees from GlaxoSmithKline group of companies, Roche, Merck, SciBase, Bristol-Myers Squibb, Novartis and Leo. He also received research funding from Merck; M. Harries: MH has received honoraria from GlaxoSmithKline group of companies for advisory boards; F. Grange: FG acted as an investigator in GlaxoSmithKline group of companies' studies and as a scientific advisor for GlaxoSmithKline group of companies; R. Ehness: RE is an employee of the GlaxoSmithKline group of companies and holds stock or stock options or restricted shares in GlaxoSmithKline group of companies; L. Benjamin: LB is an employee of the GlaxoSmithKline group of companies and holds stock or stock options or restricted shares in GlaxoSmithKline group of companies; O. Siakpere: OS is an employee of the GlaxoSmithKline group of companies and holds stock or stock options or restricted shares in GlaxoSmithKline group of companies; L. McLeod: LM is full-time employees of RTI Health Solutions, which received funding from GlaxoSmithKline group of companies to conduct this study; S. Wolowacz: SW is full-time employees of RTI Health Solutions, which received funding from GlaxoSmithKline group of companies to conduct this study; J.A. Kaye: JAK is full-time employees of RTI Health Solutions, which received funding from GlaxoSmithKline group of companies to conduct this study. I. Kontoudis: IK is an employee of the GlaxoSmithKline group of companies.